Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: Molecular targets for cell cycle arrest and apoptosis induction

Cellular Immunology

Volumn 284, Issue 1-2, 2013, Pages 129-138

  Al Sadoon, Mohamed K ^a   Rabah, Danny M ^b   Badr, Gamal ^b,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Assiut University   (Egypt)

Author keywords

Apoptosis; Bcl 2; Myeloma; Nanoparticles; Proliferation; Snake venom

Indexed keywords

B CELL ACTIVATING FACTOR; CASPASE 3; CASPASE 8; CASPASE 9; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; CYCLIN B1; CYCLIN D1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; NANOPARTICLE; PROTEIN BCL 2; SILICA NANOPARTICLE; SILICON DIOXIDE; SNAKE VENOM; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; B-CELL LYMPHOMA 2; BCL-2; CHEMOKINE; CHEMOKINE RECEPTORS; CK; CKRS; IL-6; INTERLEUKIN-6; MM; MULTIPLE MYELOMA; MYELOMA; NANOPARTICLES; NP; PROLIFERATION; REACTIVE OXYGEN SPECIES; ROS; SNAKE VENOM; WALTERINNESIA AEGYPTIA VENOM; WALTERINNESIA AEGYPTIA VENOM COMBINED WITH NANOPARTICLES; WEV; WEV+NP;

ANIMALS; APOPTOSIS; B-CELL ACTIVATING FACTOR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; ELAPID VENOMS; ELAPIDAE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NANOPARTICLES; RANDOM ALLOCATION; SPECIFIC PATHOGEN-FREE ORGANISMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882946462     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.07.016     Document Type: Article

References (52)

1. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
2. Ott M., Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 2007, 12:913-922.
3. Yip N.C., Fombon I.S., Liu P., Brown S., Kannappan V., et al. Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br. J. Cancer 2011, 104:1564-1574.
4. Rabbani Z.N., Spasojevic I., Zhang X., Moeller B.J., Haberle S., et al. Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic. Biol. Med. 2009, 47:992-1004.
5. Kello M., Mikes J., Jendzelovský R., Koval J., Fedorocko P. PUFAs enhance oxidative stress and apoptosis in tumour cells exposed to hypericin-mediated PDT. Photochem. Photobiol. Sci. 2010, 9:1244-1251.
6. Coward J.I., Kulbe H. The role of interleukin-6 in gynaecological malignancies. Cytokine Growth Factor Rev. 2012, 23:333-342.
7. Arnaldez F.I., Helman L.J. Targeting the insulin growth factor receptor 1. Hematol. Oncol. Clin. North Am. 2012, 26:527-542.
8. Fragioudaki M., Boula A., Tsirakis G., Psarakis F., Spanoudakis M., et al. Alexandrakis MG. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann. Hematol. 2012, 91:1413-1418.
9. Aggarwal R., Ghobrial I.M., Roodman G.D. Chemokines in multiple myeloma. Exp. Hematol. 2006, 34:1289-1295.
10. Kakinuma T., Hwang S.T. Chemokines, chemokine receptors, and cancer metastasis. J. Leukoc. Biol. 2006, 79:639-651.
11. Moller C., Stromberg T., Juremalm M., Nilsson K., Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003, 17:203-210.
12. Trentin L., Miorin M., Facco M., Baesso I., Carraro S., et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br. J. Haematol. 2007, 138:594-602.
13. Giuliani N., Bonomini S., Romagnani P., Lazzaretti M., Morandi F., et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 2006, 91:1489-1497.
14. Nakayama T., Hieshima K., Izawa D., Tatsumi Y., Kanamaru A., et al. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J. Immunol. 2003, 170:1136-1140.
15. Zannettino A.C., Farrugia A.N., Kortesidis A., Manavis J., To L.B., et al. Elevated serum levels of stromal derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005, 65:1700-1709.
16. Alsayed Y., Ngo H., Runnels J., Leleu X., Singha U.K. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007, 109:2708-2717.
17. Badr G., Lefevre E.A., Mohany M. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS One 2011, 6:e23741.
18. Murray A.W. Recycling the cell cycle: cyclins revisited. Cell 2004, 116:221-234.
19. Kim Y.H., Heo J.S., Han H.J. High glucose increase cell cycle regulatory proteins level of mouse embryonic stem cells via PI3-K/Akt and MAPKs signal pathways. J. Cell Physiol. 2006, 209:94-102.
20. Zuryń A., Litwiniec A., Gackowska L., Pawlik A., Grzanka A.A., et al. Expression of cyclin A, B1 and D1 after induction of cell cycle arrest in the Jurkat cell line exposed to doxorubicin. Cell Biol. Int. 2012, 36:1129-1135.
21. Terrano D.T., Upreti M., Chambers T.C. Cyclin-dependent kinase 1 mediated BclxL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell Biol. 2010, 30:640-656.
22. Chu R., Terrano D.T., Chambers T.C. Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration. Biochem. Pharmacol. 2012, 83:199-206.
23. Francis S., Markland A. Novel Snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model. Haemostasis 2001, 31:183-191.
24. Badr G., Al-Sadoon M.K., El-Toni A.M., Daghestani M. Walterinnesia aegyptia venom combined with silica nanoparticles enhances the functioning of normal lymphocytes through PI3K/AKT, NFκB and ERK signaling. Lipids Health Dis. 2012, 15(11):27.
25. Al-Sadoon M.K., Abdel-Maksoud M.A., Rabah D.M., Badr G. Induction of apoptosis and growth arrest in human breast carcinoma cells by a snake (Walterinnesia aegyptia) venom combined with silica nanoparticles: crosstalk between Bcl2 and caspase 3. Cell Physiol. Biochem. 2012, 30:653-665.
26. Son D.J., Park M.H., Chae S.J., Moon S.O., Lee J.W., et al. Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor kappa B. Mol. Cancer Ther. 2007, 6:675-683.
27. Haque F., Shu D., Shu Y., Shlyakhtenko L.S., Rychahou P.G., et al. Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today 2012, 7:245-257.
28. Park M.H., Jo M.R., Won D., Song H.S., Han S.B., et al. Snake venom toxin from Vipera lebetina turanica induces apoptosis in colon cancer cells via upregulation of ROS- and JNK-mediated death receptor expression. BMC Cancer 2012, 12:228.
29. Song J.K., Jo M.R., Park M.H., Song H.S., An B.J., et al. Cell growth inhibition and induction of apoptosis by snake venom toxin in ovarian cancer cell via inactivation of nuclear factor κB and signal transducer and activator of transcription 3. Arch. Pharm. Res. 2012, 35:867-876.
30. Wei L., Lin J., Xu W., Cai Q., Shen A., et al. Don inhibits tumor angiogenesis via suppression of hedgehog pathway in a mouse model of colorectal cancer. Int. J. Mol. Sci. 2012, 13:9419-9430.
31. Sasnauskiene A., Kadziauskas J., Vezelyte N., Jonusiene V., Kirveliene V. Apoptosis, autophagy and cell cycle arrest following photodamage to mitochondrial interior. Apoptosis 2009, 14:276-286.
32. Montero A.J., Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011, 71:1385-1396.
33. Fang J., Seki T., Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 2009, 61:290-302.
34. Park M.H., Son D.J., Kwak D.H., Song H.S., Oh K.W., et al. Snake venom toxin inhibits cell growth through induction of apoptosis in neuroblastoma cells. Arch. Pharm. Res. 2009, 32:1545-1554.
35. Liu S., Ma Z., Cai H., Li Q., Rong W., et al. Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells. Eur. J. Haematol. 2010, 84:137-144.
36. Yoshie O., Imai T., Nomiyama H. Chemokines in immunity. Adv. Immunol. 2001, 78:57-110.
37. Arya M., Patel H.R.H., Williamson M. Chemokines key players in cancer. Curr. Med. Res. Opin. 2003, 19:557-564.
38. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85.
39. Song X., Zhang G., Sun A., Guo J., Tian Z., et al. Scorpion venom component III inhibits cell proliferation by modulating NF-κB activation in human leukemia cells. Exp. Ther. Med. 2012, 4:146-150.
40. Kawauchi K., Ogasawara T., Yasuyama M., Otsuka K., Yamada O. Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies. Anticancer Agents Med. Chem. 2009, 9:1024-1038.
41. Martelli A.M., Chiarini F., Evangelisti C., Grimaldi C., Ognibene A., et al. The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol. Histopathol. 2010, 25:669-680.
42. Franke T.F., Hornik C.P., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: 497 size matters. Oncogene 2003, 22:8983-8998.
43. Vara J.Á.F., Casado E., Castro J., Cejas P., Belda-Iniesta C., et al. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30:193-204.
44. Yuan L., Wang J., Xiao H., Xiao C., Wang Y., et al. Isoorientin induces apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cancer cells. Toxicol. Appl. Pharmacol. 2012, 265:83-92.
45. Shankar S., Srivastava R.K. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int. J. Oncol. 2007, 30:905-918.
46. Qin Y., Pan X., Tang T.T., Zhou L., Gong X.G. Anti-proliferative effects of the novel squamosamide derivative (FLZ) on HepG2 human hepatoma cells by regulating the cell cycle-related proteins are associated with decreased Ca(2+)/ROS levels. Chem. Biol. Interact. 2011, 193:246-253.
47. Leiba M., Jakubikova J., Klippel S., Mitsiadesn C.S., Hideshima T., et al. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br. J. Haematol. 2012, 157:718-731.
48. Kim B., Kim S.H., Jeong S.J., Sohn E.J., Jung J.H., et al. Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells. J. Agric. Food Chem. 2012, 60:9882-9889.
49. Wang J., Sui M., Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr. Drug Metab. 2010, 11:129-141.
50. Karra N., Nassar T., Laenger F., Benita S., Borlak J. Safety and Proof-of-Concept Efficacy of Inhaled Drug Loaded Nano- and Immunonanoparticles in a c-Raf Transgenic Lung Cancer Model. Curr. Cancer Drug Targets 2013, 1:11-29.
51. Koppolu B., Bhavsar Z., Wadajkar A.S., Nattama S., Rahimi M., et al. Temperature-sensitive polymer-coated magnetic nanoparticles as a potential drug delivery system for targeted therapy of thyroid cancer. J. Biomed. Nanotechnol. 2012, 8:983-990.
52. Chen D., Tang Q., Li X., Zhou X., Zang J., et al. Biocompatibility of magnetic Fe(3) O(4) nanoparticles and their cytotoxic effect on MCF-7 cells. Int. J. Nanomed. 2012, 7:4973-4982.